Bromodomain PHD finger transcription factor (BPTF) mRNA (BPTF mRNA)

Bromodomain PHD finger transcription factor (BPTF) mRNA encodes the primary scaffold and catalytic subunit of the Nucleosome Remodeling Factor (NURF) complex, which facilitates gene transcription by sliding nucleosomes along DNA (UniProt Q12830). BPTF is characterized by its unique combination of a bromodomain and two PHD fingers, allowing it to recognize specific histone modifications like H3K4me3 and H4K16ac (PubMed: 16628203). In oncology, BPTF mRNA is frequently overexpressed, driving the proliferation and metastasis of cancers such as melanoma and non-small cell lung cancer by activating pathways like c-MYC and promoting the epithelial-mesenchymal transition (PubMed: 26237450, PubMed: 25794343). Therapeutic strategies targeting BPTF include the use of small-molecule inhibitors against its bromodomain, as well as RNA-targeting approaches like siRNA or antisense oligonucleotides designed to degrade BPTF mRNA and reduce protein levels (PubMed: 30104358). However, because BPTF is essential for normal embryonic development and the maintenance of hematopoietic stem cells, systemic inhibition poses significant safety concerns regarding developmental toxicity and hematological side effects (PubMed: 21964334). Furthermore, BPTF has been implicated in neurodevelopmental disorders, suggesting that its regulation is vital for proper brain function (PubMed: 28943116). As a target, BPTF mRNA offers a specific node for epigenetic modulation in aggressive tumors that have become resistant to standard therapies.

Other names

Fetal Alzheimer antigen 1FAC1FALZNucleosome-remodeling factor subunit BPTFNURF301

RNA interference (siRNA) or RNase H-mediated degradation (antisense oligonucleotides) to prevent translation of the BPTF protein, or small-molecule inhibition of the resulting protein's bromodomain to disrupt its interaction with acetylated histones.